Otsuka Gains Late-Stage ADHD Drug in Neurovance Acquisition
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 4 (Table of Contents)
Published: 6 Apr-2017
DOI: 10.3833/pdr.v2017.i4.2235 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to develop its central nervous system (CNS) portfolio, Otsuka Pharmaceutical has agreed to acquire Neurovance for US$100 M upfront and more than US$150 M in potential milestone payments...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS